{"name":"vTv Therapeutics","slug":"vtv-therapeutics","ticker":"","exchange":"","domain":"vtv.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":17861000,"netIncome":-26974000,"cash":89899000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"simplywall.st","summary":"We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth - simplywall.st","headline":"We Think vTv Therapeutics (NASDAQ:VTVT) Can Easily Afford To Drive Business Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPYUM3SDdEZHdFcHV1Y0pVckI2Y0RrVERCYVhEUS1lWUhNdUVObDY0VTFZbjEwM2R4dkt1a3hsTG50ck9ObnlMQXB5M2lkMm1yQ0pTSS12cnVWeG51V0tKU1JLbko2aXZ3M25UOFJGTkxUUWZ0RG0zb19hYmM1NHFucUZueE1POXJtb3QxSlczZmZzWC1LdDcyUHU2S3IyU29VSnJDWW9OZjJPdw?oc=5","date":"2026-03-12","type":"pipeline","source":"Medscape","summary":"Tachyphylaxis in Psoriasis: What’s Really Happening? - Medscape","headline":"Tachyphylaxis in Psoriasis: What’s Really Happening?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPVy1oMF9SM0ZwSlliNVVzdUljLWRCUGh3d1B5dlE0YW5oNmVXMDlVaEg1RnphY2NrZHJMbE1WSEJOaEZDeDU1RGtMSTVkMXZDeEJBZW9vWVpKQ3IzRDEzaXNoWXMxSlFnZWZkOW4wejR1dllza1V5OVAyWDZabUJIMVF0OHgyNXpFdVNUWVJIbVQwYno3VktYNUF2TFQ1aFFUZ01ucmJGVDk5QmNxZEV6XzhXdzZaS1NqLU5aV2FSZTM5anBraEJyM0pRaE1PTm1PNzAzU0RteTNpbXRHbnFEcVJxY3FFNnZhTXRoa0JlTW52dExkX2IzMll1Y2FoQ3V5UUZoU2dHWWN5TDNsbHVSSl9meTA?oc=5","date":"2026-03-12","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (VTVT) and Oxford BioMedica (OtherOXBDF)","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNcEJ4a00tVGtieE94Wm9HU0dfMl83NTZGMWlIUlEyX1p0d2Nmdl8yM3AzNmJTTC1xeXRfZjdKb3F6cHR6M0FJZG9MQVlXMHdoS01sbmhuY2ktY0hHUmJ0VUJveldVRVJ2REMyWkNWdHJ0V3NmendyMGpHS01GeUR6bHdod1RuMFhnYUVvYk5PSjlzVEdOVXBOeENFb0J1WVN1cUVteGRhTUdLX2RZ?oc=5","date":"2026-02-02","type":"regulatory","source":"Fierce Biotech","summary":"China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug - Fierce Biotech","headline":"China's Newsoara pens $135M deal for remaining rights to vTv's inflammation drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQU0stSVBUaDA3blNQVmwtX3Z5NXZHYkVWUERDSHVab1JwZHd2SjRxY01kZDIySkFyY25vLUY0UmpMTkpsSlpHV0RFZmdEQkFjLWYzUk5QMkU3bmgyZExCa2IzNUZtSUI3UW9UY1ZvWm81SHpuQXVQNmVRV0RCYlgzM2lwRnd0eFBfOGpkXzFCbFd3RHpFM0ZoM09OelBNcC1qMTdYd3lHV1FuOUZ0OC0zcE8tdHdURkZaRXoweFBWOXJvT0N6emxlR2liVEs4d0pLX1B5MXlwdWhsLVJoX3VfR1NaNWxsYkFvbENnY0dYUWExVUN5eGJ5czhxLXM1NmM?oc=5","date":"2026-02-02","type":"deal","source":"GlobeNewswire","summary":"vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737 - GlobeNewswire","headline":"vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737","sentiment":"neutral"},{"date":"2026-02-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-12-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-02","type":"pipeline","source":"simplywall.st","summary":"Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation - simplywall.st","headline":"Here's Why We're Not Too Worried About vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation","sentiment":"neutral"},{"date":"2025-11-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":0,"period":"2025-12-31"},{"value":1017000,"period":"2024-12-31"},{"value":1017000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":17861000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-26974000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":89899000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}